GlobeNewswire
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
📊
AI Sentiment
Positive
6/10
- Home
- RZLT
RZLT
Rezolute Inc. (NV)
as of 01-07-2026 4:00pm EST
$2.35
+$0.44
+23.04%
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 187.3M | IPO Year: | N/A |
| Target Price: | $12.33 | AVG Volume (30 days): | 15.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.07 - $11.46 | Next Earning Date: | 02-11-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered RZLT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.14%
71.14%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Rezolute Inc. (NV) (RZLT)
ROBERTS BRIAN KENNETH
Buy
Chief Medical Officer
RZLT Dec 16, 2025
Avg Cost/Share
$1.70
Shares
28,000
Total Value
$47,600.00
Owned After
308,352
SEC Form 4
Hogenhuis Wladimir
Buy
Director
RZLT Dec 16, 2025
Avg Cost/Share
$1.69
Shares
5,650
Total Value
$9,548.50
Owned After
119,675
SEC Form 4
Evans Daron
Buy
CFO
RZLT Dec 15, 2025
Avg Cost/Share
$1.78
Shares
45,000
Total Value
$79,577.50
Owned After
415,900
Elam Nevan C
Buy
CEO
RZLT Dec 15, 2025
Avg Cost/Share
$1.59
Shares
32,000
Total Value
$50,880.00
Owned After
641,119
SEC Form 4
Karnawat Sunil Ratilal
Buy
Chief Commercial Officer
RZLT Dec 15, 2025
Avg Cost/Share
$1.61
Shares
12,100
Total Value
$19,598.80
Owned After
71,442
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Dec 16, 2025 | Buy | $1.70 | 28,000 | $47,600.00 | 308,352 | |
| Hogenhuis Wladimir | RZLT | Director | Dec 16, 2025 | Buy | $1.69 | 5,650 | $9,548.50 | 119,675 | |
| Evans Daron | RZLT | CFO | Dec 15, 2025 | Buy | $1.78 | 45,000 | $79,577.50 | 415,900 | |
| Elam Nevan C | RZLT | CEO | Dec 15, 2025 | Buy | $1.59 | 32,000 | $50,880.00 | 641,119 | |
| Karnawat Sunil Ratilal | RZLT | Chief Commercial Officer | Dec 15, 2025 | Buy | $1.61 | 12,100 | $19,598.80 | 71,442 |
Latest Rezolute Inc. (NV) News
RZLT Breaking Stock News: Dive into RZLT Ticker-Specific Updates for Smart Investing
Insider Monkey
Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing
📉
AI Sentiment
Negative
3/10
Compare RZLT vs Leading Stocks
See how RZLT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RZLT Rezolute Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.